ATOPIC dermatitis (AD) research has uncovered a new immune signalling pathway that may help explain persistent inflammation in this common skin condition.
AD is a chronic inflammatory disease driven by immune imbalance, particularly involving T helper (Th) cell subsets such as Th2 and Th9. Despite growing evidence implicating lipid mediators in immune regulation, their precise role in AD has remained unclear. Now, new findings have identified sphingosine 1-phosphate (S1P) signalling as a key driver of cytokine production linked to disease activity.
Atopic Dermatitis and S1P Signalling Pathways
Researchers analysed CD3+ T cells and CD3– non-T cells from patients with atopic dermatitis and healthy controls using RNA sequencing. Several lipid mediator-related genes were differentially expressed, with particular emphasis on sphingosine 1-phosphate receptor 5 (S1PR5). Functional experiments showed that exposure to S1P significantly increased production of IL-13 and IL-9, two cytokines central to Th2 and Th9 responses.
Importantly, patients with atopic dermatitis exhibited higher circulating levels of S1P compared with healthy individuals, suggesting a systemic contribution to immune dysregulation. Mechanistic studies using siRNA knockdown revealed a reciprocal relationship between receptors: S1PR1 enhanced IL-13 and IL-9 production, whereas S1PR5 suppressed these cytokines.
Immune Imbalance Drives Inflammation
These findings provide new insight into how lipid signalling influences immune skewing in atopic dermatitis. By demonstrating that S1P can amplify pro-inflammatory cytokine production through S1PR1 while being counterbalanced by S1PR5, the study highlights a tightly regulated but disrupted pathway in AD.
The results suggest that an imbalance between S1PR1 and S1PR5 signalling may contribute to the exaggerated Th2/Th9-driven inflammation characteristic of atopic dermatitis. This mechanistic understanding could open the door to more targeted therapeutic strategies aimed at modulating S1P receptor activity.
However, the findings were based on in vitro experiments and require further validation in clinical settings. Future studies will be needed to determine whether targeting S1P signalling pathways can translate into effective treatments for patients with atopic dermatitis.
Overall, this research advances understanding of lipid-mediated immune regulation in atopic dermatitis and identifies a potential new axis for therapeutic intervention.
Reference
Yamamura K et al. Sphingosine 1-phosphate receptor 1 and 5 reciprocally regulate IL-13 and IL-9 production in atopic dermatitis. Allergy. 2026; DOI:10.1111/all.70299.
Featured image: Pormezz on Adobe Stock
